Peter Zdziarski: Gene Therapy vs Prophylaxis in Glanzmann Thrombasthenia
Peter Zdziarski, Vice President and Marketing Director at the Glanzmann’s Research Foundation, shared a post on LinkedIn:
”Gene Therapy vs Prophylaxis in Glanzmann Thrombasthenia
This is one of the most frequently asked questions I hear from the GT community, and it’s a crucial one.
The distinction matters:
Prophylaxis requires ongoing drug use, often weekly or bi-weekly.
Gene therapy is designed as a single procedure and has the potential for a lasting solution.
What’s important to remember is that both options are still in clinical trials. Marketing to the GT community has put a heavy spotlight on prophylaxis in recent years. For many families, this has made it seem like the only new option, when in fact gene therapy for GT has been in development for years.
That’s why staying informed is so critical. There is meaningful research happening that could change the future of treatment. Both options, and the realities behind them, deserve attention.
If you or a loved one is living with GT, I strongly encourage you to follow the groundbreaking work of Dr. David Wilcox and his team at the Medical College of Wisconsin. Their efforts are bringing real hope for a long-term solution to Glanzmann Thrombasthenia.
Knowledge is power. The more we understand the science, the costs, and the possibilities, the better prepared we are to make the best decisions for our community’s future.”
Find more information here.

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 21, 2026, 15:50Philip Osbak: Co-Editing a New Research Topic in Frontiers in Cardiovascular Medicine
-
Nov 21, 2026, 15:30Amin Marashi: How Does the Microbiome Trigger the Immune System to Suddenly Turn Against the Body’s Own Blood-Clotting Regulators?
-
Nov 21, 2026, 15:26Christina P.: Exploring Joint Involvement and Musculoskeletal Symptoms in Antiphospholipid Syndrome
-
Nov 21, 2026, 14:4410 Posts Not to Miss This Week
-
Nov 21, 2026, 14:21Two Emerging Mechanisms Linking Sickle Cell Disease to Thrombosis
-
Nov 21, 2026, 13:06Christine Faressa: Precision PRP and Platelet Biology in Musculoskeletal Care
-
Nov 21, 2026, 13:04Eyad Jamileh: Atrial Fibrillation – Bridging the Global Gaps in Diagnosis and Stroke Prevention
-
Nov 21, 2026, 12:49Thibault Veyron: Optimizing Bivalirudin Treatment in HIT
-
Nov 21, 2026, 12:44Paulus Kirchhof: Left Atrial Appendage Occlusion vs DOACs